Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma
Protein tyrosine phosphatase nonreceptor type 2 (PTPN2) is a promising target for sensitizing solid tumors to immune checkpoint blockades. However, the highly polar active sites of PTPN2 hinder drug discovery efforts. Leveraging small interfering RNA (siRNA) technology, we developed a novel glutathi...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383525001522 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849433439045943296 |
|---|---|
| author | Fu Wang Haoyu You Huahua Liu Zhuoran Qi Xuan Shi Zhiping Jin Qingyang Zhong Taotao Liu Xizhong Shen Sergii Rudiuk Jimin Zhu Tao Sun Chen Jiang |
| author_facet | Fu Wang Haoyu You Huahua Liu Zhuoran Qi Xuan Shi Zhiping Jin Qingyang Zhong Taotao Liu Xizhong Shen Sergii Rudiuk Jimin Zhu Tao Sun Chen Jiang |
| author_sort | Fu Wang |
| collection | DOAJ |
| description | Protein tyrosine phosphatase nonreceptor type 2 (PTPN2) is a promising target for sensitizing solid tumors to immune checkpoint blockades. However, the highly polar active sites of PTPN2 hinder drug discovery efforts. Leveraging small interfering RNA (siRNA) technology, we developed a novel glutathione-responsive nano-platform HPssPT (HA/PEIss@siPtpn2) to silence PTPN2 and enhance immunotherapy efficacy in hepatocellular carcinoma (HCC). HPssPT showed potent transfection and favorable safety profiles. PTPN2 deficiency induced by HPssPT amplified the interferon γ signaling in HCC cells by increasing the phosphorylation of Janus-activated kinase 1 and signal transducer and activator of transcription 1, resulting in enhanced antigen presentation and T cell activation. The nano-platform was also able to promote the M1-like polarization of macrophages in vitro. The unique tropism of HPssPT towards tumor-associated macrophages, facilitated by hyaluronic acid coating and CD44 receptor targeting, allowed for simultaneous reprogramming of both tumor cells and tumor-associated macrophages, thereby synergistically reshaping tumor microenvironment to an immunostimulatory state. In HCC, colorectal cancer, and melanoma animal models, HPssPT monotherapy provoked robust antitumor immunity, thereby sensitizing tumors to PD-1 blockade, which provided new inspiration for siRNA-based drug discovery and tumor immunotherapy. |
| format | Article |
| id | doaj-art-9b70ffcfa0f54818be030bb668ce3b65 |
| institution | Kabale University |
| issn | 2211-3835 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj-art-9b70ffcfa0f54818be030bb668ce3b652025-08-20T03:27:02ZengElsevierActa Pharmaceutica Sinica B2211-38352025-06-011562915292910.1016/j.apsb.2025.03.015Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinomaFu Wang0Haoyu You1Huahua Liu2Zhuoran Qi3Xuan Shi4Zhiping Jin5Qingyang Zhong6Taotao Liu7Xizhong Shen8Sergii Rudiuk9Jimin Zhu10Tao Sun11Chen Jiang12Key Laboratory of Smart Drug Delivery Ministry of Education, Minhang Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China; Department of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaKey Laboratory of Smart Drug Delivery Ministry of Education, Minhang Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, ChinaDepartment of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaPharmacy Department, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaDepartment of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, ChinaPASTEUR, UMR8640, Department of Chemistry, PSL University, Sorbonne Université, CNRS, Ecole Normale Supérieure, Paris 75005, FranceDepartment of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Corresponding authors.Key Laboratory of Smart Drug Delivery Ministry of Education, Minhang Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China; Corresponding authors.Key Laboratory of Smart Drug Delivery Ministry of Education, Minhang Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, ChinaProtein tyrosine phosphatase nonreceptor type 2 (PTPN2) is a promising target for sensitizing solid tumors to immune checkpoint blockades. However, the highly polar active sites of PTPN2 hinder drug discovery efforts. Leveraging small interfering RNA (siRNA) technology, we developed a novel glutathione-responsive nano-platform HPssPT (HA/PEIss@siPtpn2) to silence PTPN2 and enhance immunotherapy efficacy in hepatocellular carcinoma (HCC). HPssPT showed potent transfection and favorable safety profiles. PTPN2 deficiency induced by HPssPT amplified the interferon γ signaling in HCC cells by increasing the phosphorylation of Janus-activated kinase 1 and signal transducer and activator of transcription 1, resulting in enhanced antigen presentation and T cell activation. The nano-platform was also able to promote the M1-like polarization of macrophages in vitro. The unique tropism of HPssPT towards tumor-associated macrophages, facilitated by hyaluronic acid coating and CD44 receptor targeting, allowed for simultaneous reprogramming of both tumor cells and tumor-associated macrophages, thereby synergistically reshaping tumor microenvironment to an immunostimulatory state. In HCC, colorectal cancer, and melanoma animal models, HPssPT monotherapy provoked robust antitumor immunity, thereby sensitizing tumors to PD-1 blockade, which provided new inspiration for siRNA-based drug discovery and tumor immunotherapy.http://www.sciencedirect.com/science/article/pii/S2211383525001522Immune checkpoint blockadesLiver cancerProtein tyrosine phosphatase nonreceptor type 2Type II interferon signalingTumor-associated macrophagesTumor microenvironment |
| spellingShingle | Fu Wang Haoyu You Huahua Liu Zhuoran Qi Xuan Shi Zhiping Jin Qingyang Zhong Taotao Liu Xizhong Shen Sergii Rudiuk Jimin Zhu Tao Sun Chen Jiang Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma Acta Pharmaceutica Sinica B Immune checkpoint blockades Liver cancer Protein tyrosine phosphatase nonreceptor type 2 Type II interferon signaling Tumor-associated macrophages Tumor microenvironment |
| title | Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma |
| title_full | Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma |
| title_fullStr | Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma |
| title_full_unstemmed | Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma |
| title_short | Silencing PTPN2 with nanoparticle-delivered small interfering RNA remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma |
| title_sort | silencing ptpn2 with nanoparticle delivered small interfering rna remodels tumor microenvironment to sensitize immunotherapy in hepatocellular carcinoma |
| topic | Immune checkpoint blockades Liver cancer Protein tyrosine phosphatase nonreceptor type 2 Type II interferon signaling Tumor-associated macrophages Tumor microenvironment |
| url | http://www.sciencedirect.com/science/article/pii/S2211383525001522 |
| work_keys_str_mv | AT fuwang silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT haoyuyou silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT huahualiu silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT zhuoranqi silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT xuanshi silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT zhipingjin silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT qingyangzhong silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT taotaoliu silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT xizhongshen silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT sergiirudiuk silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT jiminzhu silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT taosun silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma AT chenjiang silencingptpn2withnanoparticledeliveredsmallinterferingrnaremodelstumormicroenvironmenttosensitizeimmunotherapyinhepatocellularcarcinoma |